TOWER trial: Blinatumomab met primary endpoint of overall survival in patients with B-cell precursor acute lymphoblastic leukemia
The results of a prespecified interim analysis have shown that the primary endpoint of improved overall survival was met in the phase 3 TOWER study.
The randomized, open-label TOWER study evaluated ...
read article